Search results for "ECK"

showing 10 items of 2091 documents

The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations

2022

BACKGROUND: To estimate the impact of oophorectomy and other treatments on the survival of breast cancer patients with a CHEK2 mutation. METHODS: Women with Stage I–III breast cancer who were treated at 17 hospitals in Poland were tested for four founder mutations in the CHEK2 gene. 974 women (10%) were positive for a CHEK2 mutation. Control patients without a CHEK2 mutation were selected from a database of patients treated over the same time period. Information on treatments received and distant recurrences were retrieved from medical records. Treatments included chemotherapy, hormonal therapy (tamoxifen) and radiation therapy. Oophorectomies were performed for the treatment of breast canc…

Cancer ResearchCheckpoint Kinase 2OncologyRisk FactorsOvariectomyMutationHumansBreast NeoplasmsFemaleGenetic Predisposition to DiseaseArticleProportional Hazards Models
researchProduct

R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair.

2010

Abstract Background CDK-inhibitors can diminish transcriptional levels of cell cycle-related cyclins through the inhibition of E2F family members and CDK7 and 9. Cyclin A1, an E2F-independent cyclin, is strongly upregulated under genotoxic conditions and functionally was shown to increase NHEJ activity. Cyclin A1 outcompetes with cyclin A2 for CDK2 binding, possibly redirecting its activity towards DNA repair. To see if we could therapeutically block this switch, we analyzed the effects of the CDK-inhibitor R-Roscovitine on the expression levels of cyclin A1 under genotoxic stress and observed subsequent DNA damage and repair mechanisms. Results We found that R-Roscovitine alone was unable …

Cancer ResearchDNA RepairDNA repairDNA damageSettore MED/06 - Oncologia MedicaCyclin DCyclin ACyclin BSettore BIO/11 - Biologia Molecolarelcsh:RC254-282RoscovitineProtein Kinase InhibitorsBIO/10 Biochimicaroscovitine doxorubicinbiologyResearchCyclin A1; Doxorubicin; Protein Kinase Inhibitors; Purines; Up-Regulation; DNA Damage; DNA Repair; Hydrogen-Ion Concentration; Cancer Research; Molecular Medicine; OncologyG2-M DNA damage checkpointHydrogen-Ion Concentrationlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensUp-RegulationOncologyDoxorubicinPurinesCancer researchbiology.proteinMolecular MedicineCyclin A1biological phenomena cell phenomena and immunityCyclin A1Cyclin A2DNA DamageMolecular cancer
researchProduct

Head and neck cancer surgery during the COVID-19 pandemic: An international, multicenter, observational cohort study

2020

Background The aims of this study were to provide data on the safety of head and neck cancer surgery currently being undertaken during the coronavirus disease 2019 (COVID-19) pandemic. Methods This international, observational cohort study comprised 1137 consecutive patients with head and neck cancer undergoing primary surgery with curative intent in 26 countries. Factors associated with severe pulmonary complications in COVID-19-positive patients and infections in the surgical team were determined by univariate analysis. Results Among the 1137 patients, the commonest sites were the oral cavity (38%) and the thyroid (21%). For oropharynx and larynx tumors, nonsurgical therapy was favored in…

Cancer ResearchInfectious Disease TransmissionSettore MED/29 - CHIRURGIA MAXILLOFACCIALEInternational CooperationSettore MED/19 - Chirurgia Plasticacoronavirusmedicine.disease_causePatient-to-Professionalsurgery0302 clinical medicine80 and over030212 general & internal medicineCoronavirusAged 80 and overUnivariate analysisCOMPLICATIONSOUTCOMESIncidence (epidemiology)Middle AgedOncologyHead and Neck Neoplasms030220 oncology & carcinogenesiscoronavirus disease 2019 (COVID-19)Cohort studyAdultmedicine.medical_specialtyInfectious Disease Transmission Patient-to-ProfessionalCritical Care03 medical and health sciencesPatient safetyYoung AdultSettore MED/28 - Malattie OdontostomatologichemedicineHumansReconstructive Surgical Proceduressevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PandemicsPersonal Protective EquipmentAgedNeoplasm StagingSurgeonsSurgical teambusiness.industryHead and neck cancerCancerCOVID-19Plastic Surgery ProceduresCAREmedicine.disease3126 Surgery anesthesiology intensive care radiologySurgerycoronavirucoronavirus; coronavirus disease 2019 (COVID-19); head and neck cancer; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); surgeryhead and neck cancerbusiness
researchProduct

Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review an…

2021

Background: Frontline immune checkpoint inhibitors (ICI)-based regimens in non-oncogene-addicted non-small-cell lung cancer (NSCLC) have been deeply investigated. To rank the available therapeutic options, we carried out a systematic review and Bayesian meta-analysis. Methods: A comprehensive search for randomized controlled trials (RCTs) of ICI regimens, and a pairwise and a network meta-analysis (NMA) with an all-comers and a stratified strategy were conducted. Endpoints were overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and treatment-related adverse events (TRAEs). Results: Nineteen RCTs involving 17 treatment regimens were included. For the all-co…

Cancer ResearchLung Neoplasmscheckpoints inhibitorsIpilimumabB7-H1 AntigenBevacizumabAntineoplastic Agents ImmunologicalNivolumabnon-small-cell lung cancersystematic reviewOncologyCarcinoma Non-Small-Cell LungHumansnetwork meta-analysisfrontline therapyESMO Open
researchProduct

Differentially methylated genes in proliferative verrucous leukoplakia reveal potential malignant biomarkers for oral squamous cell carcinoma

2021

Objectives: To explore the pathophysiology of proliferative verrucous leucoplakia (PVL) through a methylated DNA immunoprecipitation and high-throughput sequencing (MeDIP-seq) case-control study. Materials and & nbsp; Methods: Oral biopsies from ten PVL patients and five healthy individuals were obtained and used to compare their epigenetic patterns. Network biology methods and integrative analyses of MeDIP-seq and RNAseq data were applied to investigate functional relations among differentially methylated genes (DMGs). The value of selected genes as malignant biomarkers was evaluated in a large cohort of oral squamous cell carcinoma (OSCC) patients from TCGA.& nbsp; Results: A total of 464…

Cancer ResearchMeDIP-seqBiology03 medical and health sciences0302 clinical medicinemedicineHumansMethylated DNA immunoprecipitationEpigeneticsDifferential methylation030223 otorhinolaryngologyBone morphogenesisSquamous Cell Carcinoma of Head and NeckOral cancerGATA3CancerBiomarkerDNA Methylationmedicine.diseaseRNAseqDifferentially methylated regionsOncologyOral squamous cell carcinomaCase-Control Studies030220 oncology & carcinogenesisDNA methylationCancer researchProliferative verrucous leukoplakiaMouth NeoplasmsEpigeneticsGene ontologyLeukoplakia OralOral SurgeryBiomarkersHOXD10
researchProduct

Investigation of the immune infiltrate of melanoma metastases under immune checkpoint inhibition.

2017

9570 Background: Tumor infiltrating lymphocytes (TIL) play a crucial role in the therapeutic impact of immune checkpoint blockers. Methods: We investigated metastases from 56 melanoma patients before and during treatment with immune checkpoint blockers (i) immunohistochemically, (ii) with TCR repertoire profiling and (iii) analysis of the transcriptome. The patients were treated with ipilimumab (n = 25) or pembrolizumab (n = 23) or ipilimumab/nivolumab (n = 7); half of them had a disease control, the other half progressed as best response to treatment. Results: In contrast to previous reports immunohistochemical analysis of the immune infiltrate revealed no significant difference in the nu…

Cancer ResearchOncologyTumor-infiltrating lymphocytesbusiness.industryMelanomamedicineCancer researchchemical and pharmacologic phenomenamedicine.diseasebusinessImmune checkpointImmune infiltrateJournal of Clinical Oncology
researchProduct

Baseline circulating myeloid-derived suppressor cells subpopulations, neutrophils/lymphocytes ratio, and response to PD-1/PD-L1 inhibitor in non-smal…

2020

e15042 Background: Inhibitors of immune checkpoint PD-1/PD-L1 (ICI) have become a care standard in non-small cell lung cancer (NSCLC). Despite promising results, some patients cannot take advantage of immunotherapy effects. Nowadays, neither predictive nor prognostic circulating biomarkers have been found in order to select patients or to predict response to ICI. Myeloid-derived suppressor cells (MDSC) are potent immunity suppressors and may represent both a potential prognostic and a predictive biomarker. We aimed to assess the role of pretreatment circulating MDSC subpopulations on ICI outcomes in NSCLC patients. Methods: 86 NSCLC patients treated with ICI and 10 healthy donors in 3 cent…

Cancer ResearchOncologybusiness.industryCancer researchMyeloid-derived Suppressor CellMedicineNon small cellbusinessLung cancermedicine.diseasePD-L1 inhibitorImmune checkpointJournal of Clinical Oncology
researchProduct

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models

2014

Background:Cetuximab is the only targeted agent approved for the treatment of head and neck squamous cell carcinomas (HNSCC), but low response rates and disease progression are frequently reported. As the phosphoinositide 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) pathways have an important role in the pathogenesis of HNSCC, we investigated their involvement in cetuximab resistance.Methods:Different human squamous cancer cell lines sensitive or resistant to cetuximab were tested for the dual PI3K/mTOR inhibitor PF-05212384 (PKI-587), alone and in combination, both in vitro and in vivo.Results:Treatment with PKI-587 enhances sensitivity to cetuximab in vitro, even in the co…

Cancer ResearchPathologyCetuximabApoptosisHNSCCHNSCCMiceAntineoplastic Combined Chemotherapy ProtocolsNeoplasmPhosphoinositide-3 Kinase InhibitorsMice Inbred BALB CCetuximabCaspase 3TriazinesTOR Serine-Threonine KinasesCetuximab resistanceErbB ReceptorsOncologyHead and Neck NeoplasmsMonoclonalCarcinoma Squamous Cellmedicine.drugmedicine.medical_specialtyMorpholinesPI3K-mTOR inhibitorsMice NudeAntineoplastic AgentsBiologyAntibodies Monoclonal HumanizedCell Line TumorAutophagymedicineCarcinomaAnimalsHumansneoplasmsPI3K/AKT/mTOR pathwayCell Proliferationcetuximab resistanceSquamous Cell Carcinoma of Head and Necktarget therapyCell growthAutophagyCancermedicine.diseaseXenograft Model Antitumor Assaysdigestive system diseasesDrug Resistance NeoplasmPI3K7mTOR inhibitorsCancer researchTranslational TherapeuticsBritish Journal of Cancer
researchProduct

Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications.

2004

Cathepsin D is a lysosomal acid proteinase which is involved in the malignant progression of breast cancer and other gynecological tumors. Clinical investigations have shown that in breast cancer patients cathepsin D overexpression was significantly correlated with a shorter free-time disease and overall survival, whereas in patients with ovarian or endometrial cancer this phenomenon was associated with tumor aggressiveness and a degree of chemoresistance to various antitumor drugs such as anthracyclines, cis-platinum and vinca alkaloids. Therefore, a lot of research has been undertaken to evaluate the role and the prognostic value of cathepsin D also in other solid neoplasms. However, conf…

Cancer ResearchPathologymedicine.medical_specialtyLung NeoplasmsSkin NeoplasmsCathepsin DAntineoplastic AgentsBiologyDigestive System NeoplasmsCathepsin DMetastasisCentral Nervous System NeoplasmsBreast cancerSurgical oncologyNeoplasmsmedicineBiomarkers TumorNeoplasmHumansClinical significanceThyroid NeoplasmsMelanomaEndometrial cancerGeneral Medicinecathepsin D lysosomal proteinases matrix-metalloproteinases metastasis neoplasm plasminogen activator prognosis tumor progressionmedicine.diseaseNeoplasm ProteinsOncologyTumor progressionHead and Neck NeoplasmsDrug DesignCancer researchDisease ProgressionLysosomesUrogenital NeoplasmsClinicalexperimental metastasis
researchProduct

“Proliferative verrucous vs conventional leukoplakia: no significantly increased risk of HPV infection” [Oral Oncology 40 (2004) 835–840]

2005

a Department of Oral Sciences, University of Palermo, Via del Vespro 129, Palermo 90127, Italy b Department of Microbiology, University of Palermo, Via del Vespro 133, Palermo 90127, Italy c Department of Head and Neck Pathology, II University of Napoli Piazza Miraglia, 80100, Italy d Department of Biomedical sciences and Human Oncology, Section of Oral Medicine, School of Medicine and Dentistry, University of Turin, Corso Dogliotti, 14, Torino 10126, Italy e Department of Dentistry and Surgery, Pizza G. Cesare 11, Bari 70124, Italy

Cancer ResearchPathologymedicine.medical_specialtybusiness.industryGeneral surgeryHPV infectionmedicine.diseaseIncreased riskOncologyMedicineOral SurgerybusinessOral oncologyHead and neckOral medicineLeukoplakiaOral Oncology
researchProduct